• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Screening for the primary prevention of fragility fractures among adults aged 40 years and older in primary care: systematic reviews of the effects and acceptability of screening and treatment, and the accuracy of risk prediction tools
ConclusionAn offer of 2-step screening with risk assessment and BMD measurement toselected postmenopausal females with low prevalence of prior fracture probably results in a small reduction in the risk of clinical fragility fracture and hip fracture compared to no screening. These findings were most applicable to the use of clinical FRAX for risk assessment and were not replicated in theoffer-to-screen population where the rate of response to mailed screening questionnaires was low. Limited direct evidence on harms of screening were available; using study data to provide estimates, there may be a moderate degree of overdia...
Source: Systematic Reviews - March 21, 2023 Category: International Medicine & Public Health Source Type: research

Cardiovascular Risks Not Increased With Denosumab
(MedPage Today) -- AUSTIN, Texas – Denosumab (Prolia, Xgeva) carried no increased risk of cardiovascular disease or stroke when compared with zoledronic acid (Reclast, Zometa) to combat osteoporosis, researchers found. Compared with zoledronic...
Source: MedPage Today Cardiovascular - September 13, 2022 Category: Cardiology Source Type: news

Zoledronic acid and fracture risk: a meta-analysis of 12 randomized controlled trials
CONCLUSIONS: Zoledronic acid is beneficial to reduce the incidence of fracture, while its benefits to reduce the mortality are only observed at the follow-up time of 24 months.PMID:33629326 | DOI:10.26355/eurrev_202102_24865
Source: European Review for Medical and Pharmacological Sciences - February 25, 2021 Category: Drugs & Pharmacology Authors: B He J-Q Zhao M-Z Zhang Z-X Quan Source Type: research

Risk of Incident Atrial Fibrillation With Zoledronic Acid Versus Denosumab: A Propensity Score –Matched Cohort Study
ABSTRACTZoledronic acid (ZA) is an effective agent in osteoporosis and malignancy ‐related bone disease but may be associated with increased risk of atrial fibrillation (AF), although current studies disagree on this risk. To examine the risk of incident AF among patients receiving ZA compared with denosumab in the first year of treatment, we performed a new‐user, active comp arator cohort study including privately insured Americans between January 1, 2010, and June 30, 2019. Individuals aged ≥50 years without known arrhythmia or advanced kidney disease who initiated ZA were 1:1 propensity score (PS)‐matched to i...
Source: Journal of Bone and Mineral Research - November 2, 2020 Category: Orthopaedics Authors: Kristin M D'Silva, Sara Jane Cromer, Elaine W Yu, Michael Fischer, Seoyoung C Kim Tags: Original Article Source Type: research